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Adult T-cell leukemia (ATL) is an aggressive T-cell malignancy caused by human T-cell
leukemia virus type I (HTLV-1) infection and often occurs in HTLV-1-endemic areas, such
as southwestern Japan, the Caribbean islands, Central and South America, Intertropical
Africa, and Middle East. To date, many epidemiological studies have been conducted to
investigate the incidence of ATL among general population or HTLV-1 carriers and to iden-
tify a variety of laboratory, molecular, and host-specific markers to be possible predictive
factors for developing ATL because HTLV-1 infection alone is not sufficient to develop
ATL. This literature review focuses on the epidemiology of ATL and the risk factors for
the development of ATL from HTLV-1 carriers, while keeping information on the epidemi-
ology of HTLV-1 to a minimum. The main lines of epidemiological evidence are: (1) ATL
occurs mostly in adults, at least 20–30 years after the HTLV-1 infection, (2) age at onset
differs across geographic areas: the average age in the Central and South America (around
40 years old) is younger than that in Japan (around 60 years old), (3) ATL occurs in those
infected in childhood, but seldom occurs in those infected in adulthood, (4) male carriers
have about a three- to fivefold higher risk of developing ATL than female, (5) the estimated
lifetime risk of developing ATL in HTLV-1 carriers is 6–7% for men and 2–3% for women
in Japan, (6) a low anti-Tax reactivity, a high soluble interleukin-2 receptor level, a high
anti-HTLV-1 titer, and high levels of circulating abnormal lymphocytes and white blood cell
count are accepted risk factors for the development of ATL, and (7) a higher proviral load
(more than 4 copies/100 peripheral blood mononuclear cells) is an independent risk factor
for progression of ATL. Nevertheless, the current epidemiological evidence is insufficient
to fully understand the oncogenesis of ATL. Further well-designed epidemiological studies
are needed.
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INTRODUCTION
Adult T-cell leukemia (ATL) was first reported as a distinct clinical
entity in Japan in 1977 (Takatsuki et al., 1977; Uchiyama et al.,
1977). The clustering of patients in the southwestern part of Japan
propelled Japanese investigators to the interest that the disease
could be virally induced. Subsequently, human T-cell leukemia
virus type I (HTLV-1) was discovered as the causative virus for ATL
(Poiesz et al., 1980; Yoshida et al., 1982). The discoveries of ATL
and HTLV-1 ushered in the development of virology, oncology,
molecular biology, epidemiology, and other fields of medicine.
The etiological association of HTLV-1 with ATL was established
on the basis of the following findings: (1) all patients with ATL have
antibodies against HTLV-1 (Hinuma et al., 1981; Hinuma et al.,
1982), (2) geographical areas of high incidence of ATL patients cor-
respond closely with those of high incidence of HTLV-1 carriers
(The T- and B-Cell Malignancy Study Group, 1985), (3) HTLV-1
immortalizes human CD4 T cells in vitro (Hattori et al., 1981),
and (4) monoclonal integration of HTLV-1 proviral DNA was
demonstrated in ATL cells (Yamaguchi et al., 1984). Subsequently,
the Japanese Lymphoma Study Group proposed the first diagnos-
tic criteria for ATL in 1991, and the disease was classified into
four clinical subtypes; acute, lymphoma, chronic, and smoldering
(Shimoyama, 1991).
ATL patients have been reported mainly from HTLV-1-endemic
areas. The global geographical distribution of HTLV-1 seroposi-
tive individuals has been well documented (Proietti et al., 2005).
Areas with seroprevalence of more than 2% are recognized as high
endemic regions (Gessain, 1996). The main endemic areas are
Japan, the Caribbean islands, Central and South America, Central
and South Africa, a part of the Middle East and Melanesia, and
Aboriginal regions in Australia (IARC, 1996). Moreover, regional
clustering of virus positivity and high incidence of ATL has been
detected even within the endemic areas. The prevalence of HTLV-
1 carriers in Europe, North America, China, and Korea is low
(Proietti et al., 2005).
This literature review focuses on the epidemiology of ATL and
the risk factors for the development of ATL from HTLV-1 car-
riers with asymptomatic status, while keeping information on
the epidemiology of HTLV-1 to a minimum. A variety of study
designs and settings, e.g., case series, nation wide surveys, and
regional population-based studies using cancer registries were
reported to assess incidence,prevalence,and other epidemiological
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information on ATL from many countries, mostly from Japan.
However, there have been few prospective cohort studies to assess
reliable incidence rate of ATL. Readers should keep in mind that
all epidemiological studies have individual limitations in the case
accumulation and the population setting.
INCIDENCE AND PREVALENCE
JAPAN
In Japan, approximately one million individuals are carriers of
HTLV-1 (Tajima, 1990; Satake et al., 2012). Both HTLV-1 and ATL
have been shown to be endemic in southwest districts (Kyushu
and Shikoku Islands; Tajima, 1990; Satake et al., 2012). Several
epidemiological studies have been conducted to estimate annual
incidence of ATL in HTLV-1 carriers or general population, but the
exact annual incidence of ATL is still unclear. Most of the stud-
ies estimated the incidence of ATL just by merging the number
of cases of ATL in one population to the number of people in
another population such as demographic statistics, blood donors
positive for HTLV-1, or an existing group of HTLV-1 carriers. Few
prospective studies were conducted (Table 1).
Adult T-cell leukemia accounts for 51–59% of non-Hodgkin
lymphoma (NHL) in HTLV-1 endemic areas in the Kyushu dis-
trict, southwest Japan (Arisawa et al., 2000; Ohshima et al., 2002),
which was extremely higher than that of nationwide data reporting
that ATL accounts for 7.5% of all lymphomas (Lymphoma Study
Group of Japanese Pathologists, 2000).
Annual mortality of ATL
Approximately 1,000 people die of ATL each year in Japan accord-
ing to Japanese vital statistics data for 1998–2008 (Portal Site of
Official Statistics of Japan, 2012; Figure 1). This indicates that
infection with HTLV-1 was associated with approximately 1,000
deaths from ATL annually, with clustering in people aged over
50 years (Ikeda et al., 2012).
Annual incidence of ATL in nationwide studies
In the first nationwide hospital-based survey, 657 new cases of
ATL were accumulated during 1986–1987, estimating the annual
number of ATL in Japan to be approximately 700 cases (Tajima,
1990; Shimoyama, 1991). The new nationwide hospital-based sur-
vey was conducted recently, in which a total of 910 new cases of
ATL were accumulated during 2006–2007, estimating the annual
number of ATL in Japan to be approximately 1,000 cases (Yamada
et al., 2011). In the new survey, two new findings were revealed
in contrast to the first nationwide study. First, the age at diag-
nosis increased from a mean age of 52.7 years in the previous
survey to 66.0 years in the new survey (Figure 2). Second, there
were differences in the proportion of subtypes; the acute subtype
accounted for the highest percentage (60.2%), followed by the
lymphoma subtype (23.7%) in the previous survey, however, the
percentage of the lymphoma subtype increased to 34.8%, con-
trary to the decrease in the acute subtype to be 46.7% in the new
study. However, Takezaki et al. (1997) suggested that the annual
incidence of ATL based on the nationwide hospital-based survey
could be underestimated because approximately 65% of ATL cases
might have been missed due to low response of the participating
hospitals from endemic areas.
Annual incidence of ATL in HTLV-1 endemic areas
Results differ according to study methods and the HTLV-1 – posi-
tive rate of the study population. A series of cross-sectional survey
for residents in Uwajima City (population size; 290, 464, HTLV-
1-positive rate; 5.4% in men and 8.3% in women) reported that
the annual incidence of ATL was estimated to be approximately
6.1 in adults aged over 30 years per 100,000 populations (Kondo
et al., 1985, 1987, 1989). In another cross-sectional studies by
the use of the regional cancer registry data in Nagasaki prefec-
ture (an endemic area, the population size; 1.56 million), the
age-standardized annual incidence rate of ATL (among 100,000
individuals aged 30 or older) was estimated to be 10.5 for men
and 6.0 for women during 1985–1995 (Arisawa et al., 2000) and
8.7 for men and 5.5 for women during 1995–2004 (Arisawa et al.,
2009). There was no significant decrease in the overall incidence
rate between the two decades, however, age-specific incidence of
ATL among those aged over 60 years increased significantly during
1995–2004 compared to the period of 1985–1995 (Arisawa et al.,
2009).
Incidence of ATL among HTLV-1 carriers
In studies used blood donors seropositive for HTLV-1, the annual
incidence of ATL was estimated to be approximately 60 per 100,000
HTLV-1 carriers over 20 years old in Japan (Tajima, 1990) or
approximately 116 for men and 66 for women per 100,000 HTLV-
1 carriers in Saga prefecture (an endemic area, the population size;
880,000; Tokudome et al., 1989). In a study used serological survey
for residents in small cluster areas, The crude annual incidence
of ATL was estimated to be 137.7 for men and 57.4 for women
among 100,000 HTLV-1 carriers aged 30 years or older (Arisawa
et al., 2000). Furthermore, in a study performed record linkage
between the cancer registry and HTLV-1 carriers in hospital, the
crude annual incidence of ATL was estimated to be 61 per 100,000
HTLV-1 carriers (Koga et al., 2010).
Lifetime risk of ATL among HTLV-1 carriers
For HTLV-1 carriers, the lifetime risk was estimated to be 4.5%
for men and 2.6% for women in Saga prefecture (Tokudome et al.,
1989), 6.6% for men and 2.1% for women in Nagasaki prefecture
(Arisawa et al., 2000), 6.9% for men and 2.95% for women in
Uwajima City (Kondo et al., 1989), and 7.29% for men and 3.78%
for women in a hospital-based study (Koga et al., 2010).
In summary, in Japan, nearly 1,000 new cases of ATL are diag-
nosed and nearly 1,000 patients die of ATL each year over a
period of 20 years. The annual incidence of ATL among HTLV-
1 carriers is approximately 60 per 100,000 with the lifetime
risk of 6–7% for men and 2–3% for women. The incidence
was 1.35 times higher in men than in women, contrary to the
higher HTLV-1-positive rate in women than in men. ATL occurs
predominantly in elderly male carriers, and the mean age at
diagnosis increased from the early 1950s in 1980 to the late
1960s recently. Most of Japanese epidemiological studies were
population-based descriptive types using cancer registries, there-
fore those have limitations as follows; cases of smoldering ATL were
excluded; hematological diagnoses were not performed. These
limitations might have introduced an underestimation of the
actual risk.
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FIGURE 1 | Annual number of deaths from adultT-cell leukemia (ATL) during 2001–2010 in Japan.The raw data were obtained from vital statistics in the
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FIGURE 2 | Chronological changes in the mean age at diagnosis of adultT-cell leukemia (ATL) in Japan.The figure was modified from Figure 2 in Yamada
et al. (2011).
EAST ASIA (EXCLUDING JAPAN)
Although there were several reports of blood donor screening for
HTLV-1, no epidemiological study of ATL has been published from
East Asian countries other than Japan because of the lower preva-
lence of HTLV-1 (less than 0.1%). Nevertheless, several case series
of ATL were available. The first case of ATL was reported in Tai-
wan in 1985 (Chen et al., 1985), in Korea in 1987 (Lee et al.,
1987), and in China in 1995 (Zhuo et al., 1995). In Hong Kong,
since the first case of ATL was reported in 1994 (Liang, 1994), all
patients with T-cell lymphoma have been routinely screened for
HTLV-1 antibody. In a registration study of lymphoma between
1993 and 2002 in Hong Kong, six cases of ATL were diagnosed
among 5,911 lymphomas, in which ATL contributed to 0.1% of
all cases of lymphoma and 1.3% of T-cell lymphoma (Au and
Lo, 2005). Recently, 17 cases of ATL were reported from Taiwan
(Lee et al., 2010), of those approximately 40% of the patients co-
infected with HBV and HCV, which may be a characteristic of the
Taiwanese ATL.
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MIDDLE EAST
The prevalence of HTLV-1 infection among healthy subjects is
reported to be very low, less than 0.1%, in Lebanon, Saudi Arabia,
Egypt, and Kuwait (Proietti et al., 2005). However, there are some
areas with a very high rate of HTLV-1 infection.
Northeast province of Iran (Mashhad, Sabzevar, and
Neyshabour) and Urmia are known to be an endemic area for
HTLV-1, where the prevalence of HTLV-1 infection was reported
to be 0.34–0.77% in blood donors (Abbaszadegan et al., 2003;
Khameneh et al.,2008),1.7–12% in cross-sectional studies (Meytes
et al., 1990; Safai et al., 1996; Hedayati-Moghaddam et al.,
2011; Azarpazhooh et al., 2012), and 2–3% in community-based
population (Rafatpanah et al., 2011).
Romania is also suggested to be an endemic area for HTLV-
1 because antibodies to HTLV-1 were found in 0.64% of blood
donors (Paun et al., 1994), which was an extremely higher sero-
prevalence rate than in Europe and the USA. In Israel, HTLV-1
seropositive were discovered only in 0.0018% out of 276,000 blood
donations, but a very high rate of infection (over 20%) has been
identified among a segregated community of Jews originated from
the city of Mashhad in Iran (Miller et al., 1998).
Although, there are several clinical studies for ATL patients in
the Middle East (Kchour et al., 2007, 2009), epidemiological stud-
ies regarding incidence and prevalence of ATL were not available
in literature from the Middle East. There were several case reports
of ATL, most of which were Mashhad origins or Romanian origins
(Sidi et al., 1990; Veelken et al., 1996; Shtalrid et al., 2005; Bitar
et al., 2009).
UNITED STATES
HTLV-1 and ATL are extremely rare in North America. Several
ATL cases have been reported sporadically (Catovsky et al., 1982).
Most of the cases were migrants from endemic areas. A population-
based survey reported that the annual incidence in African Amer-
icans in central Brooklyn (population size; 1,184,670) was esti-
mated to be approximately 3.2 per 100,000 person-years (Levine
et al., 1999). An interesting finding in their study was that the
male-to-female ratio of 1:3 was different from the male dominance
reported in Japan. Recent cancer registry systems for hematolog-
ical malignancies allow a precise evaluation of epidemiological
features of ATL in the USA. In a recent report from the North
American Association of Central Cancer Registries (NAACCR;
Yamamoto and Goodman, 2008), a total of 431 cases (248 men
and 183 women) of ATL (ICD-O-3 code; 9,827) were registered
between 1997–2002, showing that the age adjusted incidence rate
was 0.05 for men and 0.03 for women per 100,000 population. The
study also reported a racial difference in the incidence rate, show-
ing that African Americans had the highest rates of ATL (0.12
for men and 0.13 for women per 100,000 population). A possi-
ble explanation for this observation might be the higher number
of migrants from endemic areas of the Caribbean and parts of
Sub-Saharan Africa rather than a racial difference in susceptibility.
THE CARIBBEAN
In the early 1980s, eight patients were diagnosed with ATL in the
USA, and all of them were Blacks from the Caribbean (Blattner
et al., 1982). Since then, Central/South America and the Caribbean
are known as areas of high prevalence of HTLV-1. Although there
is no concrete epidemiological report regarding the incidence or
prevalence of ATL from Central and South America, several case
series have been published. A regional registration study of Jamaica
reported a total of 126 cases of ATL (acute 46.8%, lymphoma 27%,
chronic 20.6%, and smoldering 5.6%) between January 1985 and
July 1995 (Hanchard, 1996). The mean age was 43 years old (17–
85 years old), which is similar to that reported in Brazil (43 years;
Pombo de Oliveira et al., 1995) but younger than that in Japan (50–
60 years; Yamaguchi et al., 1987). There is definite evidence that the
age at diagnosis in Central/South America and the Caribbean is
younger than that in Japan. This difference in the age at diagnosis
might be due to different environmental backgrounds.
CENTRAL AND SOUTH AMERICA
In Central and South America, HTLV-I has been shown to be
endemic mainly in populations of African ancestry and in some
populations of Japanese origin.
Brazil has the highest HTLV-1 seroprevalence rate in healthy
subjects (approximately 1%), especially in Rio de Janeiro and
Salvador (1.8%) on the northeast coast of the country where
the population is largely of African descent. ATL accounts for
approximately 30% of patients with T-cell malignancies in Brazil
(Pombo de Oliveira et al., 1995; Farias de Carvalho et al., 1997).
A Brazilian ATLL Study Group identified 195 cases of ATL in the
national registry of T-cell malignancies between 1994 and 1998
(Pombo de Oliveira et al., 1999), but no epidemiological indica-
tors were available. In Argentina, HTLV-1 infection is known to be
highly prevalent among Native Americans living in the Andes, and
ATL accounts for approximately 14.7% of patients with lymphoid
malignancies (Marin et al., 2002).
Chile is a non-tropical country but small case series of ATL
patients have been reported frequently (Cabrera et al., 1994, 1999,
2003). The characteristics of Chilean ATL were reported that the
most of patients were of Caucasian origin, and age at diagno-
sis (50 years old) was younger than Japanese patients but older
than those from other Latin American countries. According to
the recent pathological study in Chile, ATL accounts for 0.5% of
patients with of NHL (Cabrera et al., 2012).
French Guiana (population 115,000), an overseas French
administrative district located on the northeast coast of the South
American continent between Brazil and Surinam, is also known
to be an area of high endemicity for HTLV-I (Plancoulaine et al.,
1998; Talarmin et al., 1999, Pouliquen et al., 2004). Although the
population consists of various ethnic groups,a high seroprevalence
of HTLV-I (8%) and a high incidence of cases of ATL were found
among the Noirs-Marrons, an isolated population descended from
Surinam slaves (Gérard et al., 1995; Tuppin et al., 1995; Plan-
coulaine et al., 1998). An epidemiological study was performed in
French Guiana to determine the prevalence and incidence of ATL
(Gérard et al., 1995). Only 18 patients with ATL (8 acute forms,
8 lymphoma types, and 2 smoldering cases) were enrolled dur-
ing 1990–1993 and the annual crude incidence rate was estimated
to be around 3.5 per 100,000 populations. However, in a small
remote ethnic group of African origin (around 6200 inhabitants),
the annual crude incidence rate was the highest to be around 30
per 100,000 populations.
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Table 2 | Risk factors for the development of ATL with regard to the
HTLV-1 carrier status.
Reference
Host susceptibility
Vertical infection with HTLV-1 as infant Murphy et al. (1989)
Attained at an age of >50 years Many references
Male sex Many references
HLA-A*26, HLA-B*4002, HLA-B*4006, and
HLA-B*4801 (Japanese ATL)
Yashiki et al. (2001)
Co-infected with Strongyloides stercoralis
Laboratory markers
A high level of sil-2R, more than 500 U/ml Arisaw et al. (2002)
A high level of anti-HTLV-1, titer more
than×1,024
Arisaw et al. (2002)
A high level of circulating abnormal
lymphocytes, more than 0.6%
Hisada et al. (1998a)
A low level of of anti-Tax reactivity Hisada et al. (1998b)
A high level of white blood cell count, more than
9,000/µL
Imaizumi et al. (2005)
Viral markers
A higher HTLV-1 proviral load level, more than 4
copies per 100 PBMCs
Iwanaga et al. (2010)
ATL, adultT-cell leukemia; HTLV-1, humanT-cell leukemia virus type 1; HLA, human
leukocyte antigen; PBMC, peripheral blood mononuclear cell; sIL-2R, soluble
interleukin-2 receptor.
AFRICA AND EUROPE
In Africa, a high HTLV-I seroprevalence rate (>2% in the adult
population) has been reported in sub-Saharan African countries,
especially in Gabon (Hunsmann et al., 1984; Delaporte et al., 1988;
Gessain, 1996; Etenna et al., 2008; Gonçalves et al., 2010). Although
there are many reports regarding the HTLV-I seroprevalence rates
in African countries, only a few epidemiological studies of ATL
were available. In a case-control study including NHL and control
that performed in Gabon, only four cases of the 26 patients with
NHL fitted the criteria of ATL (Delaporte et al., 1993), but further
information on epidemiological feature of ATL was not available.
In Europe, HTLV-1 is endemic in Southern Italy (Manzari et al.,
1985). Several case series of ATL were reported from Europe (Man-
zari et al., 1985; Gessain et al., 1990). Most of ATL patients were
African origin from high-HTLV-1-endemic areas (West Indies,
Nigeria, and other African areas); however, some patients had no
background regarding endemic areas (Manzari et al., 1985).
RISK FACTORS FOR ATL IN HTLV-1 CARRIERS
Although a variety of genetic abnormalities due to HTLV-1 infec-
tion have been reported to explain the characteristics of ATL
oncogenesis, HTLV-1 infection alone is not sufficient to develop
ATL from HTLV-1 carrier status. Risk factors for developing ATL in
HTLV-1 carriers have been investigated in many epidemiological
and clinical studies (Table 2).
HOST SUSCEPTIBILITY
Age is a well-known risk factor for the development of ATL. ATL
occurs mostly in adults, at least 20–30 years after HTLV-1 infection.
However, the age at onset differs across geographic areas, which
may be affected by racial or environmental characteristics. In Japan
in the early 1980s, an average age at diagnosis of ATL was reported
to be individuals in their early 1950s (The T- and B-Cell Malig-
nancy Study Group, 1981, 1985), but the age at diagnosis increased
yearly, reaching 65 years in the latest nationwide survey for ATL
(Yamada et al., 2011). However, the average age at diagnosis of ATL
in Jamaican and Brazilian series was reported to be individuals in
the 1940s (43 years in Jamaica and 44 years in Brazil; Hanchard,
1996; Pombo de Oliveira et al., 1999), which is younger than that
in Japan (Yamaguchi et al., 1987).
The age at the time of HTLV-1 infection is also a very impor-
tant risk factor for the development of ATL. Individuals infected
in childhood (vertical transmission) may be at higher risk for
developing ATL (Murphy et al., 1989). ATL seldom develops in
individuals infected in adulthood, although no epidemiological
study has proven this fact. There was one case report describing
that a female HTLV-1 carrier known as conclusively transmitted
horizontally by her partner developed ATL (Sakuma et al., 1988).
To clarify whether or not ATL develops among individuals infected
in adulthood, a large prospective follow-up study is required.
Male sex is considered a risk factor for ATL. In most studies
from Japan, the incidence of ATL is two- and threefold higher
in male carriers than in female carriers, which is contrary to the
higher rate of HTLV-1 positivity in women than in men. However,
a population-based survey in central Brooklyn reported that the
annual incidence of ATL was higher in women than in men (male-
to-female ratio of 1:3; Levine et al., 1999). Modeling data from
Jamaican series also showed a higher cumulative lifetime risk of
ATL in women than in men (4.0% for men and 4.2% for women;
Murphy et al., 1989). The reason for the sex-related differences
in the incidence rate of ATL between Japan and other regions is
unknown.
It seems unlikely that there are apparent ethnical differences
in susceptibility to infection by HTLV-1 and developing ATL. A
higher incidence of ATL was found individual of African origin
than in others (Manzari et al., 1985; Gessain et al., 1990; Yamamoto
and Goodman, 2008), however, most of patients of African origin
came from HTLV-1 endemic areas.
Earlier epidemiologic studies have found that ATL patients are
more likely to have a family history of lymphoid malignancy (Ichi-
maru et al., 1979; The T- and B-Cell Malignancy Study Group,
1981). Since then, several host genetic background factors influ-
encing the onset of ATL have been investigated. Human leukocyte
antigen (HLA) is a candidate for the genetic factors controlling
the immune response against the viral antigen. Specific HLA anti-
gen alleles have been reported to be associated with an increased
risk of developing ATL (Uno et al., 1988). The allele frequencies
of HLA-A∗26, HLA-B∗4002, HLA-B∗4006, and HLA-B∗4801 were
significantly higher in ATL patients than in asymptomatic HTLV-1
carriers in southern Japan, and ATL patients possessing these alle-
les developed ATL 12.6 years earlier than patients with other alleles
(Yashiki et al., 2001). Ethnic differences in HLA alleles related to
ATL were also investigated in another study (Sonoda et al., 2011).
HTLV-1 carriers with abnormal immune system may be at
high-risk of developing ATL. Several studies reported that HTLV-
1 carriers co-infected with Strongyloides stercoralis are considered
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a high-risk group for developing ATL because of the clonal
proliferation of HTLV-1-infected lymphocytes and high proviral
load (Nakada et al., 1987; Yamaguchi et al., 1988; Plumelle et al.,
1997; Gabet et al., 2000). Satoh et al. (2002) suggested that S. ster-
coralis infection induces polyclonal expansion of HTLV-1-infected
cells by activating the interleukin 2/interleukin 2 receptor (IL-2/IL-
2R) system in dually infected carriers, which may be a precipitating
factor for ATL. The immunosuppressive state has been reported
to potentially contribute to ATL development in HTLV-1 carriers.
There were several case reports of ATL developed in HTLV-1 carri-
ers undergoing immunosuppressive treatment after living-donor
liver transplantation (Kawano et al., 2006; Yoshizumi et al., 2012)
and kidney transplantation (Hoshida et al., 2001).
LABORATORY MARKERS
Several laboratory abnormalities were found to be markers for the
development of ATL. Kamihira et al. (1994) measured prospec-
tively soluble IL-2R (sIL-2R) levels and lactate dehydrogenase
(LDH) levels in HTLV-1 carriers, reporting that the increasing
level of sIL-2R may be a more sensitive indicator of ATL than
LDH. A nested case-control study also showed that high levels of
sIL-2R (more than 500 U/mL) and HTLV-1 antibody titers (more
than 1,024) were independently associated with an increased risk
of developing ATL (Arisaw et al., 2002). Imaizumi et al. (2005)
analyzed the outcomes of 50 HTLV-1 carriers with monoclonal
proliferation of HTLV-1-infected T cells in a 20-year follow-up
study, reporting that a high white blood cell count more than
9,000/µL was a potential prognostic factor for developing ATL,
even after adjustment for age, sex, and relative lymphocyte counts.
A series of the Miyazaki Cohort Study (population size; 1,960
people, of whom 27% were HTLV-1 antibody-positive) reported
that an HTLV-1 carrier with a high anti-HTLV-1 titer (odds ratio;
1.6), a high number of circulating abnormal lymphocytes, and a
low anti-Tax reactivity were associated with a greater risk of devel-
oping ATL (Mueller et al., 1996; Hisada et al., 1998a,b). Recently,
an international ATL Cohort Consortium study by merging eight
cohorts from Japan, Jamaica, the United States, and Brazil exam-
ined serologic markers of HTLV-I pathogenesis and host immunity
in 53 ATL cases and 150 matched asymptomatic HTLV-I carriers
(Birmann et al., 2011). The study confirmed that above-median
sIL-2R and anti-Tax seropositivity were independently associated
with an increased ATL risk, and found that above-median total
immunoglobulin E levels predicted a lower ATL risk.
Aberrant expression of cell-surface antigens is usually used for
clinical routine diagnosis on ATL. ATL cells phenotypically express
CD4, CCR4, and CD25. However, data of cell-surface antigens
rarely used for a prognostic marker of ATL from HTLV-I carri-
ers. Two studies reported that expression of CD3, CD7, and CD26
on HTLV-1-infected cells were diminished in acute and chronic
ATL and those were slightly down-regulated in smoldering ATL
(Tsuji et al., 2004; Tian et al., 2011). These results suggest that the
down-regulation of those cell-surface antigens could be possible
predict markers for the early phase leukemogenesis of ATL from
HTLV-1 carriers. A resent study serially evaluated cell-surface anti-
gens on HTLV-1-infected cells in HTLV-1 carriers, smoldering
ATL, and chronic ATL, by taking into consideration the pattern
of Southern blot hybridization and proviral load (Kamihira et al.,
2012). The report suggests that the decreasing expression of CD26
and the decreasing ratio of CD26/CD25 are novel biomarkers
for prediction of clonal bands and discrimination of carriers and
smoldering ATL.
PROVIRUS-INTEGRATION STATUS
Among HTLV-1 carriers, there exist a group of cases having the
monoclonal integration of HTLV-1 proviral DNA in mononuclear
cells without signs of malignant proliferation or clinical signs and
symptoms related to leukemia (Ikeda et al., 1993). Such carriers
have been suggested to be a high-risk group of developing ATL, but
their prognosis varied from being stable carriers for long to devel-
oping ATL (Ikeda et al., 1993; Imaizumi et al., 2005). There are
only a few epidemiological studies to investigate the significance
of the provirus-integration status on non-malignant infected cells
from asymptomatic HTLV-1 carriers.
Nakada et al. (1987) reported that patients with S. stercoralis
infection and co-infected with HTLV-1 had a high frequency
(35%) of patients presenting a monoclonal integration of HTLV-1
proviral DNA in their blood lymphocytes. Carvalho and Da Fon-
seca Porto (2004) also The author also found a correlation between
monoclonal integration of proviral DNA and abnormal lympho-
cytes in peripheral blood, with a trend for greater severity of the
parasitic infection. Although several studies reported that HTLV-1
carriers co-infected with S. stercoralis are considered a high-risk
group for developing ATL (Nakada et al., 1987; Yamaguchi et al.,
1988; Plumelle et al., 1997; Gabet et al., 2000), no study investigated
the clinical significance of the monoclonal integration of HTLV-1
proviral DNA in their blood lymphocytes in HTLV-1 carriers with
S. stercoralis.
PROVIRAL LOAD
In the area of viral oncogenesis, there are accumulated data
indicating a relationship between an increased viral load and
viral-associated malignancies. HTLV-1 proviral DNA load in the
peripheral blood mononuclear cells (PBMCs) are also evaluated in
some epidemiological and clinical studies to support the hypoth-
esis that increased HTLV-1 proviral load level is an important
predictor of developing ATL.
A cross-sectional study (Manns et al., 1999) and a series of
the Miyazaki cohort study (Tachibana et al., 1992; Hisada et al.,
1998a,b; Okayama et al., 2004) reported that HTLV-1 proviral
load level was higher in HTLV-1 carriers who developed ATL
than in asymptomatic HTLV-1 carriers. However, the proviral load
was measured only in a small number of subjects in the above
literature.
Several large-scale prospective studies support results from the
previous small studies that an increased HTLV-1 proviral load is an
important predictor of developing ATL. In Japan in 2002, a nation-
wide prospective cohort study for asymptomatic HTLV-1 carriers,
the Joint Study on Predisposing Factors of ATL Development
(JSPFAD), was initiated (Yamaguchi et al., 2007) to investigate
viral- and host-specific determinants of the development of ATL
in more detail. In the cohort of 1,218 asymptomatic HTLV-1 car-
riers (426 men and 792 women), 14 subjects progressed to overt
ATL during a follow-up of 1981.2 person-years (Iwanaga et al.,
2010). All of the 14 subjects were among those with the high-
est group of baseline proviral load (range, 4.17–28.58 copies/100
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PBMCs). Multivariate Cox analyses indicated that a higher provi-
ral load (more than 4 copies/100 PBMCs) is an independent risk
factor for progression of ATL, even after adjusting for sex, age,
family history of ATL, and other possible risk factors. The result
indicated that HTLV-1 carriers with higher HTLV-1 proviral load
levels belong to the high-risk group of carriers who develop ATL
and in whom any measures to prevent the development of ATL
should be instituted.
Nevertheless, the association between HTLV-1 proviral load
and disease development remains unclear because a higher provi-
ral load is also an important predictor in patients with HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Further viral markers are needed to determine the function of a
higher HTLV-1 proviral load to direct the way to developing ATL
or developing HAM/TSP from HTLV-1 carriers.
CONCLUDING REMARKS
Although many prior studies found important epidemiological
evidence on ATL and risk factors for the development of ATL in
HTLV-1 carriers, limited data are available on the valid annual
incidence of ATL from longitudinal prospective studies. Existing
predisposing factors are still insufficient to explain the character-
istics of ATL oncogenesis. Unknown risk factors may be involved
in the acquisition of malignant characteristics of HTLV-1 infected
cells. Further well-designed epidemiological studies are needed to
fully understand the oncogenesis of ATL.
Even though the incidence of ATL is relatively low among
HTLV-1 carriers and a novel promising agent, mogamulizumab
(humanized anti-CCR4 monoclonal antibody), is released (Ishida
et al., 2003, 2012), preventing new HTLV-1 infections and the
development of ATL are major public health concerns in HTLV-1
endemic countries in the world. In Japan, there are approxi-
mately one million of HTLV-1 carriers, 1,000 new ATL cases, and
1,000 new deaths from ATL every year. However, only recently
has the Japanese government for the first time begun to imple-
ment a nationwide comprehensive package of measures cover-
ing the prevention of mother-to-child HTLV-1 transmission and
the development of medical researches on HTLV-1 and ATL
(http://www.kantei.go.jp/foreign/kan/actions/201009/13htlv_e.
html). The challenge in the next few years will be to reduce
the number of HTLV-1 carriers, to develop an easy method that
allows identification of high-risk carriers, and to implement earlier
therapeutic interventions for carriers with high-risk markers.
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